Dr. Timmerman is currently Professor, Vice-Chairman of Radiation Oncology, and Effie Marie Cain Distinguished Chair in Cancer Therapy Research at the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Timmerman joined D3’s Scientific Board in 2006 to lend his expertise in stereotactic radiosurgery to D3’s expanding advanced radiotherapy service offerings. Dr. Timmerman graduated from Iowa State University with a Bachelor of Science in Nuclear Engineering and received a Master of Science in Reactor Physics from the University of Tennessee. He obtained a Doctor of Medicine from the University of South Dakota and completed his residency in Radiation Oncology at The Johns Hopkins Hospital. Prior to joining UT Southwestern, Dr. Timmerman held clinical and academic appointments at Indiana University Medical Center and Indiana University School of Medicine. Dr. Timmerman holds several professional affiliations in radiotherapy and neuro-oncology and has served as president of several radiation oncology groups in Indiana. He is an active member of ASTRO, ACR and RTOG and has lectured throughout the country and abroad on a variety of radiotherapy related topics and emerging technologies. Dr. Timmerman has been published in many books and manuscripts on radiotherapy and stereotactic radiosurgery. He was the principal investigator or co-investigator on several prospective trials designed to evaluate the efficacy and toxicity of stereotactic body radiation therapy in lung, liver, and pelvic sites. Dr. Timmerman is the national principal investigator of Radiation Therapy Oncology Group (RTOG) trials using this therapy in patients with early stage lung cancer.

Dr. Chris Rose is currently with the Center for Radiation Therapy of Beverly Hills. In addition, he holds an appointment as Associate Clinical Professor in the Department of Radiation Oncology at University of California Los Angeles. Dr. Rose is very active in many scientific and medical organizations including ASTRO, ASCO, ACR, and the Council of Affiliated Radiation Oncology Societies (CARROS). He served as the ASTRO President in 1998 and Chairman of the Board in 1999, and served as president of CARROS in 1994. Dr. Rose is a Fellow of the ACR. Dr. Rose has been extremely active in quality assurance matters serving as assistant chairman of the ACR’s radiation oncology accreditation program. He has also been very active in technology assessment serving as vice chair for research and technology assessment, Joint Economic Committee of ASTRO and ACR.

Dr. Ling, formerly Professor and Chairman of the Department of Medical Physics, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, is presently Attending Physicist (MSKCC), Professor of Radiology (Physics) of Weill Medical College of Cornell University, and Director of Advanced Clinical Research at Varian Medical Systems. Previously, he served as Professor and Vice-Chair of the Department of Radiation Oncology at the University of California in San Francisco, California. Dr. Ling is a leading expert on the use of 3DCRT, IMRT and image guidance for radiotherapy, and has authored and co-authored numerous articles and books on these subjects. His group was one of the first to implement IMRT in routine clinical operation. Dr. Ling is active in many scientific and medical organizations including the AAPM, ASTRO, RSNA, ACR, and the Radiation Research Society (RRS). He serves on the editorial boards of the International Journal of Radiation Oncology, Biology, and Physics, Radiotherapy and Oncology, and Seminars in Radiation Oncology. Dr. Ling is a Fellow of AAPM and ASTRO, and he received the Coolidge Award of AAPM in 2004 and the Gold Medal of ASTRO in 2006.

Board Chairman

Dr. Purdy is currently Professor and Vice Chairman of the Department of Radiation Oncology and Chief of the Physics Section at UC Davis Medical Center in Sacramento, California. Dr. Purdy has been extremely active in research and development related to 3-D treatment planning and conformal radiation therapy (3DCRT) for the past two decades. Over this period, he has authored and co-authored numerous articles and books on 3DCRT, including the development and implementation of IMRT. Dr. Purdy is internationally recognized as an expert in radiation oncology quality assurance (QA) matters and computer-aided radiation therapy, particularly 3DCRT and IMRT, and is regularly invited to speak on these issues. He has also been very active in developing methodology for QA of multi-institutional 3DCRT dose escalation trials in the U.S. and serves as the current Director of the Image-Guided Therapy Center in St. Louis, an advanced technology clinical trials QA and support center funded by the National Cancer Institute to support cooperative groups, such as the Radiation Therapy Oncology Group (RTOG), 3DCRT and IMRT clinical trials.

Dr. Purdy is very active in many scientific and medical organizations including the American Association of Physicists in Medicine (AAPM), American Society of Therapeutic Radiology and Oncology (ASTRO), the American College of Radiology (ACR), the Radiation Therapy Oncology Group (RTOG), and the American College of Medical Physics (ACMP). Dr. Purdy has served as the AAPM President, Chairman of the Board of Chancellors of the ACMP, and served on the ASTRO Board of Directors, being that organization’s first elected medical physicist board member. He is currently the Senior Editor (Physics) for the International Journal of Radiation Oncology, Biology, and Physics. Dr. Purdy is a Fellow in the AAPM, the ACMP, and the ACR. He has received many prestigious awards including the 1996 ACMP Marvin M.D. Williams Professional Achievement Award and the 1997 AAPM William D. Coolidge Award Award for Distinguished Contributions to Medical Physics, the two highest honors bestowed by U.S. medical physics societies. In 2000, he was selected as recipient of the ASTRO Gold Medal, the largest society of radiation oncologists and scientists working in this field in the world.

Chief Medical Officer

PhD DABR – Chief Scientific Officer, D3 Oncology Solutions

Dr. Lalonde completed a PhD in medical biophysics at Princess Margaret Hospital, University of Toronto, Canada, and a clinical medical physics residency at the Hamilton Regional Cancer Center in Hamilton, Canada. Previously, he has worked for NOMOS Corporation, where he assisted in the development of one of the first IMRT planning systems, CORVUS, and was scientific director of the BAT project, an ultrasound image-guided therapy system. A veteran in the clinical medical physics field, Dr. Lalonde has worked at cancer centers in both Canada and the U.S. Dr. Lalonde has held appointments at Temple University School of Medicine and McMaster University, and is currently an Assistant Professor at the University of Pittsburgh School of Medicine. His current research interests are in stereotactic body radiotherapy and the clinical application of IMRT and IGRT.

Ms. Lokay is the President and CEO for D3 Oncology Solutions, a commercial subsidiary of the University of Pittsburgh Medical Center (UPMC) focused on improving the quality and value of cancer care on a global basis. Before joining UPMC in 2008, Ms. Lokay was a Senior Vice President at US Oncology where she worked for over twelve years leading a number of their service lines, including iKnowMed, an oncology specific EHR company, Innovent, their payer-facing pathways and disease management business, outcomes research, radiation oncology, as well as pharmacy and therapeutics. She started her career at US Oncology providing finance and accounting leadership for the corporation, including the role of interim Chief Financial Officer in 2000. Ms. Lokay is a former certified public accountant with a BBA in Accounting from the University of Texas at Austin.

Mr. Ross has over twenty years experience in the Radiation Oncology market. He currently serves as the Chief Operating Officer of D3 Oncology Solutions, the industry leader in the provision of IMRT Treatment Planning, Training, and Continuing Education. Prior to assuming his leadership role at D3 Oncology Solutions in June 2007, Mr. Ross served as operations Director for UPMC Cancer Centers, where he led the expansion and daily operations of the UPMC Cancer Centers Radiation Oncology network. During his six year tenure, UPMC Cancer Centers established a Hub and Spoke model of 21 cancer centers spanning Western PA, with an eventual expansion into the international market in Ireland, and has become an internationally recognized Cancer program both in terms of clinical excellence and operational performance. Mr. Ross began his career as a Radiation Therapist involved in the daily treatment of cancer patients at the Western Pennsylvania Hospital, before progressing into roles as a chief therapist at Wheeling Hospital and Radiation Oncology Manager at Pittsburgh Mercy Hospital. Mr. Ross holds a Masters Degree in Business Administration from Indiana University of Pennsylvania, a Bachelors Degree in Health Science from Carlow University, and an Associates Degree in Radiation Therapy Technology.